Clinical Trials | September 23, 2025
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
Importantly, the combination of giredestrant and everolimus was well tolerated
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
The inspection concluded with zero form 483 observations
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Subscribe To Our Newsletter & Stay Updated
